This page shows the latest TauRx Pharmaceuticals news and features for those working in and with pharma, biotech and healthcare.
A specialist in tau-based research into Alzheimer’s disease, TauRx Pharmaceuticals has shared initial data from LUCIDITY, a phase 3 clinical trial. ... The trial assessed TauRx’s lead investigative oral drug, HMTM, which has been tested in 598 people
modulator EVP 0962 (EnVivo Pharmaceuticals); the metal protein-attenuating compound called PBT 2 (Prana Biotechnology); and ELND 005 (Speranza Therapeutics). ... Of these, TRx 0237 (leuco-methylthioninium, TauRx Pharmaceuticals), an oral agent shown to
Financial terms of the deal were not disclosed. Other companies with an interest in developing tau-targeted products include TauRx Pharmaceuticals, which in November 2012 received $111.8m from Malaysian investment
More from news
Approximately 1 fully matching, plus 2 partially matching documents found.
Medscape delivers dynamic, innovative education to optimize learner engagement and patient outcomes worldwide....